Pralsetinib (Gavreto)

Status:: Do Not Prescribe (DNP)
Decision Date:: September 2022

Comments

DNP: NICE TA812 Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer. NHSE commissioned.

Black Drug Classifications

2: Have a lack of data on safety compared with standard therapy
4: Have a lack of data on cost-effectiveness compared with standard therapy